Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
NCT ID: NCT06256432
Last Updated: 2025-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
54 participants
INTERVENTIONAL
2024-04-17
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to test whether the administration of low doses of ambrisentan can help patients with Hepatorenal Syndrome and to determine if it is safe. Ambrisentan is a drug that is approved for the treatment of high blood pressure in the lungs at higher doses.
This clinical trial will compare the safety and effects of ambrisentan to another drug called terlipressin, which is commonly used to treat patients with hepatorenal syndrome.
The main questions the clinical trial aims to answer are:
* Does ambrisentan help the kidney function of the patient?
* Does ambrisentan help prevent death in patients with Hepatorenal Syndrome?
* Does ambrisentan prevent Hepatorenal Syndrome from reappearing?
While in the hospital, trial participants will receive either one of two doses of ambrisentan or terlipressin. If in the first 4 days, ambrisentan is not helpful, the patient may be eligible to receive terlipressin. Patients assigned to receive ambrisentan will continue taking this medication at home after leaving the hospitals and until they complete 60 days of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Compare the Efficacy of Nor Adrenaline and Terlipressin vs Step up Terlipressin Therapy in Hepatorenal Syndrome
NCT01649037
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
NCT03827200
To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure
NCT02573727
Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1
NCT03822091
Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock
NCT06556472
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ambrisentan - Low Dose 1
Liquid solution for oral administration, dose \< 250 µg/day, up to 60 days
Ambrisentan
Endothelin receptor antagonist
Ambrisentan - Low Dose 2
Liquid solution for oral administration, dose \< 250 µg/day, up to 60 days
Ambrisentan
Endothelin receptor antagonist
Terlipressin
Sterile lyophilized powder, to be reconstituted for intravenous administration, at a dose indicated by the study investigator and administered for up to 14 days, considering the following recommendation: 1 mg terlipressin administered in 2-minute bolus every 6 hours for 3 days, and dose of terlipressin increased to 2 mg every 6 hours in the absence of a decrease of at least 30% in serum creatinine by day 4
Terlipressin
Terlipressin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ambrisentan
Endothelin receptor antagonist
Terlipressin
Terlipressin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years and ≤ 70 years.
* Male or non-pregnant, non-lactating female. Women of child-bearing potential must have a confirmed negative serum pregnancy test at the time of screening and must use a highly effective contraceptive method throughout the study such as combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tube occlusion, vasectomised partner, and sexual abstinence and until one month after completing treatment with the study medication. In the case of hormonal contraception, women should have been on a stable regimen for a minimum of three months before study enrolment. Women not of child-bearing potential include post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy). Men must use an effective contraception method (i.e., condom + diaphragm/spermicidal gel or foam, or vasectomy), and should not donate semen during the study. Men are considered to be fertile from the time of puberty, except for those men with permanent sterility secondary to bilateral orchiectomy.
* Cirrhosis of the liver by laboratory examination, clinical history or biopsy.
* History of ascites.
* Increase in serum creatinine ≥ 0.3 mg/dl (26.5 µmol/L) from a value obtained in the 7 days prior to admission, OR a serum creatinine ≥ 1.5 mg/dl (132.6 µmol/L) and is ≥ 1.5-fold above the most recent and lowest value obtained in the last 3 months.
* The subject has no clinical and/or haemodynamic evidence of intravascular volume depletion; or has undergone at least 12 hours of diuretic withdrawal and fluid resuscitation to discard or treat intravascular volume depletion (such as difficulty in establishing volume status, volume status is assessed as equivocal, or there is clinical and/or haemodynamic evidence of intravascular volume depletion), and no significant improvement in serum creatinine has been observed.
Exclusion Criteria
* Mean arterial pressure (MAP) \< 60 mmHg.
* Large Volume Paracentesis (LVP) in the 3 days prior to screening.
* Sepsis, uncontrolled bacterial infection or less than 2 days anti-infective therapy for documented or suspected bacterial infection.
* Total bilirubin \> 8 mg/dL (137 µmol/L).
* Serum sodium \< 125 mmol/L.
* International Normalised Ratio (INR) ≥ 3.5.
* Proteinuria ≥ 1000 mg/dL.
* Microhaematuria \> 50 red blood cells per high power field.
* Clinically significant casts on urinalysis, including granular casts.
* History or evidence of obstructive uropathy or parenchymal renal disease on ultrasound or other imaging.
* Subject with a recent history of circulatory shock defined as MAP \< 60 mmHg within 5 days prior to screening requiring vasopressors or subjects requires circulatory support with vasopressors during screening.
* Subject requiring oxygen supplementation or mechanical ventilation.
* Recent exposure to nephrotoxic agents or exposure to radiographic contrast agents within 72 hrs prior to screening.
* Superimposed acute liver failure/injury due to factors other than alcohol, including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom \[Amanita\] poisoning).
* Severe cardiovascular disease, including, but not limited to, unstable angina, pulmonary oedema, congestive heart failure (NYHA ≥ II), or persisting symptomatic peripheral vascular disease, myocardial infarction or stable chronic angina within the past 12 months, or any other cardiovascular disease judged by the Investigator to be severe.
* Subject has a history of Transjugular Intrahepatic Portosystemic shunt (TIPS).
* Subject with acute variceal bleeding at the time of screening who may undergo pre-emptive TIPS or is anticipated to be treated with terlipressin.
* Current or recent Renal Replacement Therapy (RRT) within 30 days of enrolment, or anticipation of RRT in the next 3 days after screening.
* Hepatocellular Carcinoma (HCC) beyond the Milan criteria or other malignancy affecting survival beyond 6 months.
* Participation in a study of an investigational medical product or device within the last 30 days preceding screening.
* Hepatic Encephalopathy with West Haven Grade III or IV.
* Current or recent (30 days prior to enrolment) treatment with endothelin receptor antagonists, including ambrisentan.
* Estimated life expectancy of less than 3 days.
* Known allergy or sensitivity to ambrisentan or propylene glycol.
* History of Idiopathic Pulmonary Fibrosis.
* Subject is unable or unwilling to follow instructions or comply with study procedures.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Noorik Biopharmaceuticals AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iker Navarro, MD
Role: STUDY_DIRECTOR
Noorik Biopharmaceuticals AG
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aster CMI Hospital
Bangalore, Karnataka, India
Sir HN Reliance Hospital Foundation
Mumbai, Maharashtra, India
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, India
Asian Institute of Gastroenterology (AIG)
Hyderabad, Telangana, India
Ganesh Shankar Vidyarthi Memorial (GSVM) Medical College
Kanpur, Uttar Pradesh, India
Medanta Multi Super Specialty Hospital
Lucknow, Uttar Pradesh, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mallikarjun Sakpal, MD
Role: primary
Ranjini R, MD
Role: backup
Akash Shukla, MD
Role: primary
Dr Shalimar, MD
Role: primary
Vinay Kumar, MD
Role: primary
Abhai Verna, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G; International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015 Apr;64(4):531-7. doi: 10.1136/gutjnl-2014-308874. Epub 2015 Jan 28. No abstract available.
Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet. 1996 Jun 29;347(9018):1842-3. No abstract available.
Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013;38(4):345-54. doi: 10.1159/000355540. Epub 2013 Oct 5.
Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest. 1977 Nov;37(7):635-42. doi: 10.3109/00365517709100657.
Moore K. Endothelin and vascular function in liver disease. Gut. 2004 Feb;53(2):159-61. doi: 10.1136/gut.2003.024703.
Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med. 1992 Dec 17;327(25):1774-8. doi: 10.1056/NEJM199212173272502.
Zipprich A, Gittinger F, Winkler M, Dollinger MM, Ripoll C. Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: A proof of concept study. Liver Int. 2021 Mar;41(3):554-561. doi: 10.1111/liv.14757. Epub 2021 Jan 5.
Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension. 2009 Jul;54(1):113-9. doi: 10.1161/HYPERTENSIONAHA.109.132670. Epub 2009 Jun 8.
Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2008 Jan;47(1):160-8. doi: 10.1002/hep.21940.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-003-CRD005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.